Ultragenyx Pharmaceutical | RARE - Operating Expenses


Ultragenyx Pharmaceutical reported $305M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Kyowa Hakko Kirin JPY 108.95B 75M Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Moderna USD 1.78B 242M Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xoma USD 22.84M 1.67M Sep/2024